Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study Research Letter
| Authors: | van de Donk, N. W. C. J.; Bahlis, N.; Costa, L. J.; Mateos, M. V.; Nooka, A. K.; Perrot, A.; Garfall, A. L.; Thaman, P.; Qi, K.; Uhlar, C.; Chastain, K.; Doyle, M.; Usmani, S. Z. |
| Title: | Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study |
| Keywords: | adult; clinical article; controlled study; letter; multiple myeloma; phase 1 clinical trial; human; male; female; coronavirus disease 2019; teclistamab |
| Journal Title: | Blood Cancer Journal |
| Volume: | 14 |
| ISSN: | 2044-5385 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2024-10-21 |
| Start Page: | 186 |
| Language: | English |
| DOI: | 10.1038/s41408-024-01160-1 |
| PUBMED: | 39433732 |
| PROVIDER: | scopus |
| PMCID: | PMC11494165 |
| DOI/URL: | |
| Notes: | Letter -- Source: Scopus |
